Project description DEENESFRITPL Special cover to minimise bladder cancer recurrence Bladder cancer is the ninth most frequently-diagnosed cancer worldwide, with the highest incidence rates observed in men in Southern and Western Europe, North America, as well in certain countries in Northern Africa or Western Asia. In Europe, a total of 118 000 new cases and 52 000 deaths are estimated annually. While treatment depends on how advanced the cancer is, there is a high risk of tumour recurrence. The U-TURBT project developed an innovative disposable device (by the same name) to cover and seal the bladder portion affected by the tumour. The cover stops tumour cell spillage and dissemination, minimising the risk of recurrence. It will also be upgraded to permit bladder tumour resection and extrication. Show the project objective Hide the project objective Objective Bladder cancer represents the 9th most common malignancy worldwide and the 4th most common in men. Globally approximately 2.5M people suffer from it, with 420,000 newly diagnosed cases each year. In Europe, a total of 118,000 new cases and 52,000 deaths are estimated annually. With population growth and ageing, the absolute incidence of bladder cancer might be further escalating.Despite the increasing incidences, the current treatments remain ineffective. The gold standard Trans-Urethral Resection of Bladder Tumour (TURBT) has up to 61% risk of tumour recurrence due to incomplete removal or tumour cell implantation during the procedure.CML introduces U-TURBT, an innovative disposable device for the treatment of bladder cancer. By covering and sealing the portion of bladder affected by the tumour, it avoids tumour cell spillage and dissemination. By minimising the risk of recurrence, U-TURBT improves patients’ health and quality of life, and cuts down the expenses of the healthcare providers relative to additional treatments.During the feasibility assessment, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. During the second phase of innovation project, CML will upgrade the device to permit en bloc bladder tumour resection and extrication. Large scale clinical trial will then be initiated for obtaining CE mark as a medical device Fields of science medical and health sciencesclinical medicineoncologybladder cancermedical and health sciencesclinical medicinesurgerysocial scienceseconomics and businessbusiness and managementbusiness modelsnatural scienceschemical sciencesorganic chemistryalcoholsmedical and health scienceshealth sciencesnutritionobesity Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator CAMBRIDGE MECHATRONICS LIMITED Net EU contribution € 50 000,00 Address UNIT 17, BLOCK 6 THE WESTBROOK CENT CB4 1YG CAMBRIDGE United Kingdom See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region East of England East Anglia Cambridgeshire CC Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
